lancet
infecti
diseas
paton
colleagu
report
result
clinic
trial
investig
chloroquin
prevent
infl
uenza
show
antimalari
drug
eff
ect
diseas
acquisit
clinic
cours
chloroquin
hydroxyl
analogu
hydroxychloroquin
becam
plausibl
candid
treatment
sever
viral
diseas
mani
report
invitro
inhibitori
eff
ect
diff
erent
virus
although
eff
ect
prove
highli
reproduc
antivir
eff
ect
chloroquin
vivo
shown
mous
model
coronaviru
infect
antivir
eff
ect
hydroxychloroquin
shown
two
clinic
trial
individu
infect
result
howev
could
reproduc
equival
dose
chloroquin
sever
possibl
reason
exist
failur
translat
invitro
eff
ect
invivo
set
narrow
therapeut
index
ie
ratio
cytotox
concentr
cc
antivir
eff
ectiv
concentr
ec
ec
micromolar
rang
three
order
magnitud
greater
necessari
inhibit
chloroquinesensit
malaria
parasitesth
microorgan
drug
origin
prescrib
poor
penetr
specifi
c
tissu
high
interstrain
variabl
eff
ect
chloroquin
infl
uenza
virus
mayb
futur
chloroquin
deriv
improv
pharmacokinet
abl
bridg
gap
invitro
invivo
eff
ect
treatment
rnaviru
infect
think
monotherapi
avoid
potenti
rapid
develop
drug
resist
therefor
chloroquin
hydroxychloroquin
could
still
consid
treatment
combin
antivir
drug
eff
ect
merit
consider
inhibit
chloroquin
cellular
protein
includ
pglycoprotein
multidrugresistanceassoci
protein
extrud
drug
cell
anatom
compart
although
current
antiinfl
uenza
drug
act
extracellular
transmembran
target
new
intracytosol
drug
target
viral
life
cycl
explor
colleagu
propos
use
chloroquin
therapeut
agent
viral
infect
eg
sar
aid
pathogenesi
characteris
deleteri
strong
persist
immun
activ
chloroquin
well
known
immunomodulatori
agent
shown
continu
use
treatment
rheumatoid
arthriti
immunemedi
diseas
context
poor
effi
caci
drug
pandem
infl
uenza
diseas
sever
shown
paton
colleagu
explain
absenc
antivir
eff
ect
vivo
also
fact
pandem
infl
uenza
show
patient
benign
clinic
cours
gener
uncompl
immunemedi
damag
individu
hivaid
chloroquin
repeatedli
report
eff
ectiv
counteract
deleteri
immun
activ
associ
diseas
recent
studi
murray
colleagu
show
chloroquin
signifi
cantli
decreas
express
marker
treatment
failur
progress
aid
associ
immun
activ
induc
viral
replic
cell
induc
downmodul
marker
associ
immuneactivationinduc
lymphocyt
mitosi
memori
cell
invitro
invivo
antiinfl
ammatori
eff
ect
good
agreement
one
reason
behind
agreement
suggest
recent
studi
hydroxychloroquin
show
drug
accumul
high
concentr
lymphoid
tissu
patient
infect
hiv
reproduc
invivo
eff
ect
quionolin
antimalari
could
use
ad
new
strategi
restrict
hiv
reservoir
aim
counteract
residu
immun
activ
antiretrovir
therapi
favour
sustain
viral
replic
anatom
sanctuari
target
activ
prolifer
central
transit
memori
cell
harbour
silent
copi
hiv
provir
dna
contribut
mainten
viru
genom
treatment
notwithstand
poor
effi
caci
chloroquin
infl
uenza
prevent
result
report
paton
colleagu
help
address
process
drug
reposit
treatment
infecti
diseas
depart
infecti
parasit
immunemedi
diseas
istituto
superior
di
vial
regina
elena
rome
itali
andreasavarino
issit
declar
confl
ict
interest
lancet
infecti
diseas
today
sarah
hawk
colleagu
review
eff
ect
intervent
increas
coverag
screen
treatment
syphili
pregnanc
uptak
test
treatment
advers
pregnanc
outcom
avert
studi
time
remind
syphili
disappear
remain
major
although
entir
prevent
caus
death
newborn
babi
syphili
estim
respons
almost
perinat
death
per
year
subsaharan
africa
alon
mani
stillbirth
larg
ignor
globalhealth
commun
rare
count
includ
nation
statist
estim
global
burden
diseas
mention
millennium
develop
goal
mdg
lancet
stillbirth
seri
welcom
attempt
redress
balanc
lawn
colleagu
estim
million
stillbirth
occur
annual
develop
countri
northern
tanzania
stillbirth
women
screen
syphili
pregnanc
could
attribut
syphili
adjust
possibl
caus
live
born
infant
death
syphili
occur
fi
rst
week
life
mani
countri
make
progress
toward
achiev
mdg
reduc
mortal
two
third
children
younger
yearsneonat
mortal
fi
rst
week
life
remain
high
account
total
mortal
earli
neonat
mortal
fi
rst
week
life
